IDEX CORP /DE/ - Quarter Report: 2010 September (Form 10-Q)
Table of Contents
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
Washington, D.C. 20549
Form 10-Q
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
For the quarterly period ended September 30, 2010 | ||
OR
|
||
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number 1-10235
IDEX CORPORATION
(Exact Name of Registrant as
Specified in its Charter)
Delaware (State or other jurisdiction of incorporation or organization) |
36-3555336 (I.R.S. Employer Identification No.) |
|
1925 West Field Court, Lake Forest, Illinois (Address of principal executive offices) |
60045 (Zip Code) |
Registrants
telephone number:
(847) 498-7070
Indicate by check mark whether the registrant: (1) has
filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past
90 days.
Yes þ No o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files).
Yes þ No o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
Large accelerated filer þ | Accelerated filer o | Non-accelerated filer o | Smaller reporting company o |
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange Act).
Yes o No þ
Number of shares of common stock of IDEX Corporation outstanding
as of October 30, 2010: 81,885,485 (net of treasury shares).
TABLE OF
CONTENTS
Table of Contents
PART I.
FINANCIAL INFORMATION
Item 1. | Financial Statements. |
IDEX CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except share and per share amounts)
(unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except share and per share amounts)
(unaudited)
September 30, 2010 | December 31, 2009 | |||||||
ASSETS
|
||||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$ | 206,054 | $ | 73,526 | ||||
Receivables, less allowance for doubtful accounts of $6,498 at
September 30, 2010 and $6,160 at December 31, 2009
|
210,188 | 183,178 | ||||||
Inventories net
|
191,698 | 159,463 | ||||||
Other current assets
|
53,019 | 35,545 | ||||||
Total current assets
|
660,959 | 451,712 | ||||||
Property, plant and equipment net
|
187,021 | 178,283 | ||||||
Goodwill
|
1,208,756 | 1,180,445 | ||||||
Intangible assets net
|
281,978 | 281,354 | ||||||
Other noncurrent assets
|
7,747 | 6,363 | ||||||
Total assets
|
$ | 2,346,461 | $ | 2,098,157 | ||||
LIABILITIES AND SHAREHOLDERS EQUITY | ||||||||
Current liabilities
|
||||||||
Trade accounts payable
|
$ | 94,299 | $ | 73,020 | ||||
Accrued expenses
|
163,119 | 98,730 | ||||||
Short-term borrowings
|
11,070 | 8,346 | ||||||
Dividends payable
|
12,366 | 9,586 | ||||||
Total current liabilities
|
280,854 | 189,682 | ||||||
Long-term borrowings
|
480,559 | 391,754 | ||||||
Deferred income taxes
|
158,536 | 148,806 | ||||||
Other noncurrent liabilities
|
90,754 | 99,811 | ||||||
Total liabilities
|
1,010,703 | 830,053 | ||||||
Commitment and contingencies
|
||||||||
Shareholders equity
|
||||||||
Preferred stock:
|
||||||||
Authorized: 5,000,000 shares, $.01 per share par value;
Issued: None
|
| | ||||||
Common stock:
|
||||||||
Authorized: 150,000,000 shares, $.01 per share par value
|
||||||||
Issued: 84,263,419 shares at September 30, 2010 and
83,510,320 shares at December 31, 2009
|
843 | 835 | ||||||
Additional paid-in capital
|
425,769 | 401,570 | ||||||
Retained earnings
|
975,702 | 896,977 | ||||||
Treasury stock at cost: 2,565,194 shares at
September 30, 2010 and 2,540,052 at December 31, 2009
|
(57,449 | ) | (56,706 | ) | ||||
Accumulated other comprehensive income (loss)
|
(9,107 | ) | 25,428 | |||||
Total shareholders equity
|
1,335,758 | 1,268,104 | ||||||
Total liabilities and shareholders equity
|
$ | 2,346,461 | $ | 2,098,157 | ||||
See Notes to Condensed Consolidated Financial Statements.
1
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
(unaudited)
Three Months Ended |
Nine Months Ended |
|||||||||||||||
September 30, | September 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
Net sales
|
$ | 373,731 | $ | 323,249 | $ | 1,107,855 | $ | 986,317 | ||||||||
Cost of sales
|
219,598 | 194,191 | 651,360 | 602,964 | ||||||||||||
Gross profit
|
154,133 | 129,058 | 456,495 | 383,353 | ||||||||||||
Selling, general and administrative expenses
|
88,170 | 79,789 | 266,961 | 242,687 | ||||||||||||
Restructuring expenses
|
3,524 | 2,752 | 6,422 | 8,253 | ||||||||||||
Operating income
|
62,439 | 46,517 | 183,112 | 132,413 | ||||||||||||
Other income (expense) net
|
(1,101 | ) | 1,382 | (608 | ) | 806 | ||||||||||
Interest expense
|
4,162 | 3,951 | 11,195 | 13,212 | ||||||||||||
Income before income taxes
|
57,176 | 43,948 | 171,309 | 120,007 | ||||||||||||
Provision for income taxes
|
18,612 | 14,171 | 55,722 | 39,703 | ||||||||||||
Net income
|
$ | 38,564 | $ | 29,777 | $ | 115,587 | $ | 80,304 | ||||||||
Basic earnings per common share
|
$ | 0.47 | $ | 0.37 | $ | 1.42 | $ | 1.00 | ||||||||
Diluted earnings per common share
|
$ | 0.47 | $ | 0.37 | $ | 1.40 | $ | 0.99 | ||||||||
Share data:
|
||||||||||||||||
Basic weighted average common shares outstanding
|
80,517 | 79,740 | 80,322 | 79,642 | ||||||||||||
Diluted weighted average common shares outstanding
|
81,938 | 80,879 | 81,749 | 80,535 | ||||||||||||
See Notes to Condensed Consolidated Financial Statements.
2
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY
(in thousands except share amounts)
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY
(in thousands except share amounts)
(unaudited)
Accumulated Other Comprehensive Income (Loss) | ||||||||||||||||||||||||||||
Net |
||||||||||||||||||||||||||||
Actuarial |
||||||||||||||||||||||||||||
Losses |
||||||||||||||||||||||||||||
and Prior |
||||||||||||||||||||||||||||
Service |
||||||||||||||||||||||||||||
Costs on |
||||||||||||||||||||||||||||
Pensions |
||||||||||||||||||||||||||||
and Other |
Cumulative |
|||||||||||||||||||||||||||
Common Stock |
Post- |
Unrealized Losses |
||||||||||||||||||||||||||
and Additional |
Cumulative |
Retirement |
on Derivatives |
Total |
||||||||||||||||||||||||
Paid-In |
Retained |
Translation |
Benefit |
Designated as Cash |
Treasury |
Shareholders |
||||||||||||||||||||||
Capital | Earnings | Adjustment | Plans | Flow Hedges | Stock | Equity | ||||||||||||||||||||||
Balance, December 31, 2009
|
$ | 402,405 | $ | 896,977 | $ | 59,399 | $ | (27,258 | ) | $ | (6,713 | ) | $ | (56,706 | ) | $ | 1,268,104 | |||||||||||
Net income
|
| 115,587 | | | | | 115,587 | |||||||||||||||||||||
Other comprehensive income, net of tax:
|
||||||||||||||||||||||||||||
Cumulative translation adjustment
|
| | (12,187 | ) | | | | (12,187 | ) | |||||||||||||||||||
Amortization of post retirement obligations
|
| | | 728 | | | 728 | |||||||||||||||||||||
Net change on derivatives designated as cash flow hedges
|
| | | | (23,076 | ) | | (23,076 | ) | |||||||||||||||||||
Other comprehensive loss
|
| | | | | | (34,535 | ) | ||||||||||||||||||||
Comprehensive income
|
| | | | | | 81,052 | |||||||||||||||||||||
Issuance of 795,589 shares of common stock from issuance of
unvested shares, exercise of stock options and deferred
compensation plans, net of tax benefit
|
11,349 | | | | | | 11,349 | |||||||||||||||||||||
Unvested shares surrendered for tax withholding
|
| | | | | (743 | ) | (743 | ) | |||||||||||||||||||
Share-based compensation
|
12,858 | | | | | | 12,858 | |||||||||||||||||||||
Cash dividends declared $.45 per common share
|
| (36,862 | ) | | | | | (36,862 | ) | |||||||||||||||||||
Balance, September 30, 2010
|
$ | 426,612 | $ | 975,702 | $ | 47,212 | $ | (26,530 | ) | $ | (29,789 | ) | $ | (57,449 | ) | $ | 1,335,758 | |||||||||||
See Notes to Condensed Consolidated Financial Statements.
3
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Nine Months |
||||||||
Ended |
||||||||
September 30, | ||||||||
2010 | 2009 | |||||||
Cash flows from operating activities
|
||||||||
Net income
|
$ | 115,587 | $ | 80,304 | ||||
Adjustments to reconcile net income to net cash provided by
operating activities:
|
||||||||
Loss on sale of fixed assets
|
| 447 | ||||||
Depreciation and amortization
|
25,608 | 23,482 | ||||||
Amortization of intangible assets
|
19,280 | 18,411 | ||||||
Amortization of debt issuance expenses
|
371 | 232 | ||||||
Stock-based compensation expense
|
12,858 | 12,781 | ||||||
Deferred income taxes
|
1,210 | 4,302 | ||||||
Excess tax benefit from stock-based compensation
|
(3,271 | ) | (1,523 | ) | ||||
Changes in (net of the effect from acquisitions):
|
||||||||
Receivables
|
(19,684 | ) | 20,100 | |||||
Inventories
|
(27,664 | ) | 20,774 | |||||
Trade accounts payable
|
14,698 | (12,762 | ) | |||||
Accrued expenses
|
22,004 | (9,005 | ) | |||||
Other net
|
(3,651 | ) | 131 | |||||
Net cash flows provided by operating activities
|
157,346 | 157,674 | ||||||
Cash flows from investing activities
|
||||||||
Additions to property, plant and equipment
|
(26,006 | ) | (18,346 | ) | ||||
Acquisition of businesses, net of cash acquired
|
(68,330 | ) | | |||||
Proceeds from fixed assets disposals
|
| 3,582 | ||||||
Other net
|
| 329 | ||||||
Net cash flows used in investing activities
|
(94,336 | ) | (14,435 | ) | ||||
Cash flows from financing activities
|
||||||||
Borrowings under credit facilities for acquisitions
|
53,866 | | ||||||
Borrowings under credit facilities
|
7,896 | 64,906 | ||||||
Proceeds from issuance of senior notes
|
96,762 | | ||||||
Payments under credit facilities
|
(73,377 | ) | (174,203 | ) | ||||
Dividends paid
|
(34,082 | ) | (28,969 | ) | ||||
Proceeds from stock option exercises
|
8,725 | 3,692 | ||||||
Excess tax benefit from stock-based compensation
|
3,271 | 1,523 | ||||||
Other net
|
(743 | ) | (1,204 | ) | ||||
Net cash flows provided by (used in) financing activities
|
62,318 | (134,255 | ) | |||||
Effect of exchange rate changes on cash and cash equivalents
|
7,200 | 4,092 | ||||||
Net increase in cash
|
132,528 | 13,076 | ||||||
Cash and cash equivalents at beginning of year
|
73,526 | 61,353 | ||||||
Cash and cash equivalents at end of period
|
$ | 206,054 | $ | 74,429 | ||||
Supplemental cash flow information
|
||||||||
Cash paid for:
|
||||||||
Interest
|
$ | 10,118 | $ | 13,400 | ||||
Income taxes
|
46,347 | 31,853 | ||||||
Significant non-cash activities:
|
||||||||
Debt acquired with acquisition of business
|
722 | | ||||||
Issuance of unvested shares
|
2,917 | 4,895 |
See Notes to Condensed Consolidated Financial Statements.
4
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
(unaudited)
1. | Basis of Presentation and Significant Accounting Policies |
The Condensed Consolidated Financial Statements of IDEX
Corporation (IDEX or the Company) have
been prepared in accordance with the instructions to
Form 10-Q
under the Securities Exchange Act of 1934, as amended. The
statements are unaudited but include all adjustments, consisting
only of recurring items, except as noted, which the Company
considers necessary for a fair presentation of the information
set forth herein. The results of operations for the three and
nine months ended September 30, 2010 are not necessarily
indicative of the results to be expected for the entire year.
The condensed consolidated financial statements and
Managements Discussion and Analysis of Financial Condition
and Results of Operations should be read in conjunction with the
Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2009.
Adoption
of New Accounting Standards
In January 2010, the Financial Accounting Standards Board
(FASB) issued ASU
2010-06,
Fair Value Measurements and Disclosures (Topic 820).
This Update provides amendments to Subtopic
820-10 and
related guidance within U.S. Generally Accepted Accounting
Principles (GAAP) to require disclosure of the
transfers in and out of Levels 1 and 2 and a schedule for
Level 3 that separately identifies purchases, sales,
issuances and settlements and requires more detailed disclosures
regarding valuation techniques and inputs. The Company adopted
this standard on its effective date, see Note 12 for
disclosures associated with the adoption of this standard.
In February 2010, the FASB issued ASU
2010-09,
Subsequent Events (Topic 855). This update provides
amendments to Subtopic
855-10-50-4
and related guidance within U.S. GAAP to clarify that an
SEC registrant is not required to disclose the date through
which subsequent events have been evaluated. This change
alleviates potential conflicts between Subtopic
855-10 and
the SECs requirements. The Company adopted this update on
its effective date.
2. | Restructuring |
The Company has recorded restructuring costs as a result of cost
reduction efforts and facility closings. Accruals have been
recorded based on these costs and primarily consist of employee
termination benefits. We record expenses for employee
termination benefits based on the guidance of Accounting
Standards Codification (ASC) 420, Exit or
Disposal Cost Obligations. These expenses are included in
Restructuring expenses in the Condensed Consolidated Statements
of Operations while the related restructuring accruals are
included in Accrued expenses in our Condensed Consolidated
Balance Sheets.
During the three and nine months ended September 30, 2010,
the Company recorded an additional $3.5 million and
$6.4 million, respectively, of pre-tax restructuring
expenses related to our 2009 restructuring initiative for
employee severance related to employee reductions across various
functional areas as well as facility closures resulting from the
Companys cost savings initiatives. In the three and nine
months ended September 30, 2009, the Company recorded
pre-tax restructuring expenses totaling $2.8 million and
$8.3 million, respectively, related to this same
initiative. The 2009 initiative has included severance benefits
for over 600 employees. This initiative is expected to be
completed by the end of 2010 with an expected additional total
cost of approximately $1.0-$2.0 million during the
remainder of 2010.
Pre-tax restructuring expenses, by segment, for the three months
ended September 30, 2010 were as follows:
Severance |
||||||||||||
Costs | Exit Costs | Total | ||||||||||
(in thousands) | ||||||||||||
Fluid & Metering Technologies
|
$ | 1,153 | $ | | $ | 1,153 | ||||||
Health & Science Technologies
|
2,102 | 269 | 2,371 | |||||||||
Dispensing Equipment
|
| | | |||||||||
Fire & Safety/Diversified Products
|
| | | |||||||||
Total restructuring costs
|
$ | 3,255 | $ | 269 | $ | 3,524 | ||||||
5
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Pre-tax restructuring expenses, by segment for the three months
ended September 30, 2009, were as follows:
Severance |
||||||||||||
Costs | Exit Costs | Total | ||||||||||
(in thousands) | ||||||||||||
Fluid & Metering Technologies
|
$ | 657 | $ | | $ | 657 | ||||||
Health & Science Technologies
|
841 | 184 | 1,025 | |||||||||
Dispensing Equipment
|
630 | | 630 | |||||||||
Fire & Safety/Diversified Products
|
24 | | 24 | |||||||||
Corporate/Other
|
202 | 214 | 416 | |||||||||
Total restructuring costs
|
$ | 2,354 | $ | 398 | $ | 2,752 | ||||||
Pre-tax restructuring expenses, by segment, for the nine months
ended September 30, 2010 were as follows:
Severance |
||||||||||||
Costs | Exit Costs | Total | ||||||||||
(in thousands) | ||||||||||||
Fluid & Metering Technologies
|
$ | 1,864 | $ | 202 | $ | 2,066 | ||||||
Health & Science Technologies
|
2,948 | 323 | 3,271 | |||||||||
Dispensing Equipment
|
120 | | 120 | |||||||||
Fire & Safety/Diversified Products
|
477 | | 477 | |||||||||
Corporate/Other
|
396 | 92 | 488 | |||||||||
Total restructuring costs
|
$ | 5,805 | $ | 617 | $ | 6,422 | ||||||
Pre-tax restructuring expenses, by segment for the nine months
ended September 30, 2009, were as follows:
Severance |
||||||||||||
Costs | Exit Costs | Total | ||||||||||
(in thousands) | ||||||||||||
Fluid & Metering Technologies
|
$ | 2,552 | $ | 490 | $ | 3,042 | ||||||
Health & Science Technologies
|
2,123 | 596 | 2,719 | |||||||||
Dispensing Equipment
|
347 | 860 | 1,207 | |||||||||
Fire & Safety/Diversified Products
|
474 | | 474 | |||||||||
Corporate/Other
|
441 | 370 | 811 | |||||||||
Total restructuring costs
|
$ | 5,937 | $ | 2,316 | $ | 8,253 | ||||||
Restructuring accruals of $5.0 million and
$6.9 million as of September 30, 2010 and
December 31, 2009, respectively, are reflected in Accrued
expenses in our Condensed Consolidated Balance Sheets as follows:
(In thousands) | ||||
Balance at January 1, 2010
|
$ | 6,878 | ||
Restructuring costs
|
6,422 | |||
Payments/Utilization
|
(8,286 | ) | ||
Balance at September 30, 2010
|
$ | 5,014 | ||
3. | Acquisitions |
On April 15, 2010, the Company acquired Seals, Ltd
(Seals), a leading provider of proprietary high
performance seals and advanced sealing solutions for a diverse
range of global industries, including analytical
instrumentation, semiconductor/solar and process technologies.
Seals consists of the Polymer Engineering and Perlast divisions.
Seals Polymer Engineering division focuses on sealing
solutions for hazardous duty applications. The Perlast division
produces highly engineered seals for analytical instrumentation,
pharmaceutical, electronics,
6
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
and food applications. Headquartered in Blackburn, England,
Seals has annual revenues of approximately $32.0 million
(£21 million). Seals operates as part of the Health
and Science Technologies segment. The Company acquired Seals for
an aggregate purchase price of $54.0 million, consisting of
$51.3 million in cash and the assumption of approximately
$2.7 million of debt related items. The cash payment was
financed with borrowings under the Companys Credit
Facility. Goodwill and intangible assets recognized as part of
this transaction were $29.9 million and $17.1 million,
respectively. The $29.9 million of goodwill is not
deductible for tax purposes.
On July 21, 2010, the Company acquired OBL, S.r.l.
(OBL), a leading provider of mechanical and
hydraulic diaphragm pumps. OBL provides polymer blending systems
and related accessories for a diverse range of global
industries, including water, waste water, oil and gas,
petro-chemical and power generation markets. Headquartered in
Milan, Italy, with annual revenues of approximately
$10.9 million (8.5 million), OBL operates within
IDEXs Fluid and Metering Technologies segment as part of
the Water and Waste Water Group. The Company acquired OBL for an
aggregate purchase price of $15.4 million, of which
$12.8 million in cash was paid as of September 30,
2010 and approximately $2.6 million in cash will be paid in
the fourth quarter. Goodwill and intangible assets recognized as
part of this transaction were $7.6 million and
$4.1 million, respectively. The $7.6 million of
goodwill is not deductible for tax purposes.
On September 17, 2010, the Company acquired Periflo, a
leading provider of peristaltic pumps for the industrial and
municipal water and wastewater markets. Periflo offers a
complete family of peristaltic hose pumps for a wide variety of
applications. Headquartered in Loveland, Ohio, with annual
revenues of approximately $3.5 million, Periflo operates
within IDEXs Fluid and Metering Technologies segment as
part of the Water and Waste Water Group. The Company acquired
Periflo for an aggregate purchase price of $4.2 million,
consisting entirely of cash. Goodwill and intangible assets
recognized as part of this transaction were $2.3 million
and $0.8 million, respectively. The $2.3 million of
goodwill is deductible for tax purposes.
The purchase price for Seals, OBL and Periflo has been allocated
to the assets acquired and liabilities assumed based on
estimated fair values at the date of the acquisition. The
purchase price allocation is preliminary and further refinements
may be necessary pending certain asset and liability valuations.
The results of operations for these acquisitions have been
included within the Companys financial results from the
date of the acquisition. The Company does not consider these
acquisitions to be material to its results of operations for any
of the periods presented.
4. | Business Segments |
The Company consists of four reportable business segments:
Fluid & Metering Technologies, Health &
Science Technologies, Dispensing Equipment and Fire &
Safety/Diversified Products.
The Fluid & Metering Technologies Segment designs,
produces and distributes positive displacement pumps, flow
meters, injectors, and other fluid-handling pump modules and
systems and provides flow monitoring and other services for
water and wastewater. The Health & Science
Technologies Segment designs, produces and distributes a wide
range of precision fluidics and sealing solutions, including
very high precision, low-flow rate pumping solutions required in
analytical instrumentation, clinical diagnostics and drug
discovery, high performance molded and extruded biocompatible
medical devices and implantables, air compressors used in
medical, dental and industrial applications, and precision gear
and peristaltic pump technologies that meet exacting OEM
specifications. The Dispensing Equipment Segment produces
precision equipment for dispensing, metering and mixing
colorants, paints, and hair colorants and other personal care
products used in a variety of retail and commercial businesses
around the world. The Fire & Safety/Diversified
Products Segment produces firefighting pumps and controls,
rescue tools, lifting bags and other components and systems for
the fire and rescue industry, and engineered stainless steel
banding and clamping devices used in a variety of industrial and
commercial applications.
7
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company evaluates segment performance based on several
factors, of which operating income is the primary financial
measure. Intersegment sales are accounted for at fair value as
if the sales were to third parties. Information on the
Companys business segments is presented below.
Three Months |
Nine Months |
|||||||||||||||
Ended |
Ended |
|||||||||||||||
September 30, | September 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
(In thousands) | ||||||||||||||||
Net sales
|
||||||||||||||||
Fluid & Metering Technologies:
|
||||||||||||||||
External customers
|
$ | 176,685 | $ | 156,781 | $ | 523,753 | $ | 470,271 | ||||||||
Intersegment sales
|
196 | 158 | 553 | 686 | ||||||||||||
Total group sales
|
176,881 | 156,939 | 524,306 | 470,957 | ||||||||||||
Health & Science Technologies:
|
||||||||||||||||
External customers
|
103,745 | 75,365 | 288,868 | 219,305 | ||||||||||||
Intersegment sales
|
574 | 773 | 3,459 | 4,837 | ||||||||||||
Total group sales
|
104,319 | 76,138 | 292,327 | 224,142 | ||||||||||||
Dispensing Equipment:
|
||||||||||||||||
External customers
|
26,352 | 25,580 | 100,992 | 104,111 | ||||||||||||
Intersegment sales
|
128 | | 177 | | ||||||||||||
Total group sales
|
26,480 | 25,580 | 101,169 | 104,111 | ||||||||||||
Fire & Safety/Diversified Products:
|
||||||||||||||||
External customers
|
66,949 | 65,523 | 194,242 | 192,630 | ||||||||||||
Intersegment sales
|
44 | 1 | 143 | 3 | ||||||||||||
Total group sales
|
66,993 | 65,524 | 194,385 | 192,633 | ||||||||||||
Intersegment elimination
|
(942 | ) | (932 | ) | (4,332 | ) | (5,526 | ) | ||||||||
Total net sales
|
$ | 373,731 | $ | 323,249 | $ | 1,107,855 | $ | 986,317 | ||||||||
Operating income (loss)
|
||||||||||||||||
Fluid & Metering Technologies
|
$ | 31,554 | $ | 25,755 | $ | 93,928 | $ | 70,731 | ||||||||
Health & Science Technologies
|
21,661 | 14,287 | 60,649 | 34,703 | ||||||||||||
Dispensing Equipment
|
2,711 | (311 | ) | 19,062 | 13,112 | |||||||||||
Fire & Safety/Diversified Products
|
17,045 | 15,932 | 44,032 | 42,790 | ||||||||||||
Corporate office and other
|
(10,532 | ) | (9,146 | ) | (34,559 | ) | (28,923 | ) | ||||||||
Total operating income
|
$ | 62,439 | $ | 46,517 | $ | 183,112 | $ | 132,413 | ||||||||
5. | Earnings Per Common Share |
Earnings per common share (EPS) are computed by
dividing net income by the weighted average number of shares of
common stock (basic) plus common stock equivalents outstanding
(diluted) during the period. Common stock equivalents consist of
stock options, which have been included in the calculation of
weighted average shares outstanding using the treasury stock
method, unvested shares, and shares issuable in connection with
certain deferred compensation agreements (DCUs).
ASC 260 Earnings Per Share, (ASC 260)
concludes that all outstanding unvested share-based payment
awards that contain rights to nonforfeitable dividends
participate in undistributed earnings with common shareholders.
If awards are considered participating securities, the Company
is required to apply the two-class method of
8
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
computing basic and diluted earnings per share. The Company has
determined that its outstanding unvested shares are
participating securities. Accordingly, earnings per common share
are computed using the two-class method prescribed by
ASC 260. Net income attributable to common shareholders was
reduced by $0.3 million and $0.2 million for the three
months ended September 30, 2010 and 2009, respectively. Net
income attributable to common shareholders was reduced by
$1.0 million and $0.6 million for the nine months
ended September 30, 2010 and 2009, respectively.
Basic weighted average shares reconciles to diluted weighted
average shares as follows:
Three |
Nine |
|||||||||||||||
Months |
Months |
|||||||||||||||
Ended September 30, | Ended September 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
(in thousands) | ||||||||||||||||
Basic weighted average common shares outstanding
|
80,517 | 79,740 | 80,322 | 79,642 | ||||||||||||
Dilutive effect of stock options, unvested shares, and DCUs
|
1,421 | 1,139 | 1,427 | 893 | ||||||||||||
Diluted weighted average common shares outstanding
|
81,938 | 80,879 | 81,749 | 80,535 | ||||||||||||
Options to purchase approximately 2.9 million and
2.5 million shares of common stock as of September 30,
2010 and 2009, respectively, were not included in the
computation of diluted EPS because the exercise price was
greater than the average market price of the Companys
common stock and, therefore, the effect of their inclusion would
be antidilutive.
6. | Inventories |
The components of inventories as of September 30, 2010 and
December 31, 2009 were:
September 30, |
December 31, |
|||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Raw materials and component parts
|
$ | 130,034 | $ | 113,777 | ||||
Work-in-process
|
25,260 | 20,669 | ||||||
Finished goods
|
54,677 | 43,626 | ||||||
Total
|
209,971 | 178,072 | ||||||
Less inventory reserves
|
18,273 | 18,609 | ||||||
Total
inventories-net
|
$ | 191,698 | $ | 159,463 | ||||
Inventories are stated at the lower of cost or market. Cost,
which includes material, labor, and factory overhead, is
determined on a FIFO basis.
9
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
7. | Goodwill and Intangible Assets |
The changes in the carrying amount of goodwill for the nine
months ended September 30, 2010, by reportable segment,
were as follows:
Fluid & |
Health & |
Fire & Safety/ |
||||||||||||||||||
Metering |
Science |
Dispensing |
Diversified |
|||||||||||||||||
Technologies | Technologies | Equipment | Products | Total | ||||||||||||||||
(In thousands) | ||||||||||||||||||||
Balance at December 31, 2009
|
$ | 533,979 | $ | 392,379 | $ | 104,973 | $ | 149,114 | $ | 1,180,445 | ||||||||||
Foreign currency translation
|
(4,854 | ) | 172 | (4,146 | ) | (2,628 | ) | (11,456 | ) | |||||||||||
Acquisitions
|
9,916 | 29,851 | | | 39,767 | |||||||||||||||
Balance at September 30, 2010
|
$ | 539,041 | $ | 422,402 | $ | 100,827 | $ | 146,486 | $ | 1,208,756 | ||||||||||
ASC 350 Goodwill and Other Intangible Assets
requires that goodwill be tested for impairment at the reporting
unit level on an annual basis and between annual tests if an
event occurs or circumstances change that would more likely than
not reduce the fair value of the reporting unit below its
carrying value. Annually on October 31st, goodwill and
other acquired intangible assets with indefinite lives are
tested for impairment. The Company concluded that the fair value
of each of the reporting units was in excess of the carrying
value as of October 31, 2009. The Company did not consider
there to be any triggering event that would require an interim
impairment assessment, therefore none of the goodwill or other
acquired intangible assets with indefinite lives were tested for
impairment during the nine months ended September 30, 2010.
The following table provides the gross carrying value and
accumulated amortization for each major class of intangible
asset at September 30, 2010 and December 31, 2009:
At September 30, 2010 | At December 31, 2009 | |||||||||||||||||||||||||||
Gross |
Weighted |
Gross |
||||||||||||||||||||||||||
Carrying |
Accumulated |
Average |
Carrying |
Accumulated |
||||||||||||||||||||||||
Amount | Amortization | Net | Life | Amount | Amortization | Net | ||||||||||||||||||||||
Amortizable intangible assets:
|
||||||||||||||||||||||||||||
Patents
|
$ | 9,844 | $ | (4,883 | ) | $ | 4,961 | 11 | $ | 9,914 | $ | (4,289 | ) | $ | 5,625 | |||||||||||||
Trade names
|
66,349 | (13,216 | ) | 53,133 | 15 | 63,589 | (10,144 | ) | 53,445 | |||||||||||||||||||
Customer relationships
|
167,986 | (44,347 | ) | 123,639 | 12 | 157,890 | (32,422 | ) | 125,468 | |||||||||||||||||||
Non-compete agreements
|
4,543 | (3,773 | ) | 770 | 4 | 4,268 | (3,356 | ) | 912 | |||||||||||||||||||
Unpatented technology
|
42,532 | (8,706 | ) | 33,826 | 14 | 36,047 | (6,240 | ) | 29,807 | |||||||||||||||||||
Other
|
5,958 | (2,409 | ) | 3,549 | 10 | 6,236 | (2,239 | ) | 3,997 | |||||||||||||||||||
Total amortizable intangible assets
|
297,212 | (77,334 | ) | 219,878 | 277,944 | (58,690 | ) | 219,254 | ||||||||||||||||||||
Banjo trade name
|
62,100 | | 62,100 | 62,100 | | 62,100 | ||||||||||||||||||||||
$ | 359,312 | $ | (77,334 | ) | $ | 281,978 | $ | 340,044 | $ | (58,690 | ) | $ | 281,354 | |||||||||||||||
The Banjo trade name is an indefinite lived intangible asset
which is tested for impairment on an annual basis or more
frequently if events or changes in circumstances indicate that
the asset might be impaired.
10
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
8. | Accrued Expenses |
The components of accrued expenses as of September 30, 2010
and December 31, 2009 were:
September 30, |
December 31, |
|||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Payroll and related items
|
$ | 49,079 | $ | 39,315 | ||||
Management incentive compensation
|
16,767 | 12,157 | ||||||
Income taxes payable
|
10,310 | 3,757 | ||||||
Insurance
|
4,647 | 4,375 | ||||||
Warranty
|
4,233 | 4,383 | ||||||
Deferred revenue
|
4,102 | 4,480 | ||||||
Restructuring
|
5,014 | 6,878 | ||||||
Forward setting interest rate contract (see Note 11)
|
42,189 | | ||||||
Other
|
26,778 | 23,385 | ||||||
Total accrued expenses
|
$ | 163,119 | $ | 98,730 | ||||
9. | Other Noncurrent Liabilities |
The components of noncurrent liabilities as of
September 30, 2010 and December 31, 2009 were:
September 30, |
December 31, |
|||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Pension and retiree medical obligations
|
$ | 69,633 | $ | 67,426 | ||||
Interest rate exchange agreements
|
4,659 | 10,497 | ||||||
Deferred revenue
|
4,539 | 5,353 | ||||||
Other
|
11,923 | 16,535 | ||||||
Total other noncurrent liabilities
|
$ | 90,754 | $ | 99,811 | ||||
10. | Borrowings |
Borrowings at September 30, 2010 and December 31, 2009
consisted of the following:
September 30, |
December 31, |
|||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Credit Facility
|
$ | 284,866 | $ | 298,732 | ||||
Term Loan
|
90,000 | 95,000 | ||||||
Euro-denominated Senior Notes
|
110,241 | | ||||||
Other borrowings
|
6,522 | 6,368 | ||||||
Total borrowings
|
491,629 | 400,100 | ||||||
Less current portion
|
11,070 | 8,346 | ||||||
Total long-term borrowings
|
$ | 480,559 | $ | 391,754 | ||||
The Company maintains a $600.0 million unsecured domestic,
multi-currency bank revolving credit facility (Credit
Facility), which expires on December 21, 2011. In
2008, the Credit Facility was amended to allow the Company to
designate certain foreign subsidiaries as designated borrowers.
Upon approval from the lenders, the
11
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
designated borrowers were allowed to receive loans under the
Credit Facility. A designated borrower sublimit was established
as the lesser of the aggregate commitments or
$100.0 million. As of the amendment date, Fluid Management
Europe B.V., (FME) was approved by the lenders as a designated
borrower. On March 16, 2010, IDEX UK Ltd. (IDEX
UK) was also approved by the lenders as a designated
borrower which allowed them to receive loans under the Credit
Facility. FME had no borrowings under the Credit Facility as of
September 30, 2010. IDEX UKs borrowings under the
Credit Facility at September 30, 2010 were
£22.0 million ($34.9 million). As the IDEX
UKs borrowings under the Credit Facility are British Pound
denominated and the cash flows that will be used to make
payments of principal and interest are predominately denominated
in British Pound, the Company does not anticipate any
significant foreign exchange gains or losses in servicing this
debt.
At September 30, 2010 there was $284.9 million
outstanding under the Credit Facility. The net available
borrowing under the Credit Facility as of September 30,
2010, was approximately $315.1 million. Interest is payable
quarterly on the outstanding borrowings at the bank agents
reference rate. Interest on borrowings based on LIBOR plus an
applicable margin is payable on the maturity date of the
borrowing, or quarterly from the effective date for borrowings
exceeding three months. The applicable margin is based on the
Companys senior, unsecured, long-term debt rating and can
range from 24 basis points to 50 basis points. Based
on the Companys credit rating at September 30, 2010,
the applicable margin was 40 basis points. An annual Credit
Facility fee, also based on the Companys credit rating, is
currently 10 basis points and is payable quarterly.
At September 30, 2010 the Company had one interest rate
exchange agreement related to the Credit Facility. The interest
rate exchange agreement, expiring in January 2011, effectively
converted $250.0 million of floating-rate debt into
fixed-rate debt at an interest rate of 3.25%. This fixed rate
consists of the fixed rate on the interest rate exchange
agreement and the Companys current margin of 40 basis
points on the Credit Facility.
On April 18, 2008, the Company completed a
$100.0 million unsecured senior bank term loan agreement
(Term Loan) with covenants consistent with the
existing Credit Facility and a maturity on December 21,
2011. At September 30, 2010, there was $90.0 million
outstanding under the Term Loan with $7.5 million included
within short term borrowings. Interest under the Term Loan is
based on the bank agents reference rate or LIBOR plus an
applicable margin and is payable at the end of the selected
interest period, but at least quarterly. The applicable margin
is based on the Companys senior, unsecured, long-term debt
rating and can range from 45 to 100 basis points. Based on
the Companys current debt rating, the applicable margin is
80 basis points. The Term Loan requires a repayment of
$7.5 million in April 2011, with the remaining balance due
on December 21, 2011. The Company used the proceeds from
the Term Loan to pay down existing debt outstanding under the
Credit Facility.
At September 30, 2010 the Company had an interest rate
exchange agreement related to the Term Loan that expires in
December 2011. With a current notional amount of
$90.0 million, the agreement effectively converted
$100.0 million of floating-rate debt into fixed-rate debt
at an interest rate of 4.00%. The fixed rate consists of the
fixed rate on the interest rate exchange agreement and the
Companys current margin of 80 basis points on the
Term Loan.
On April 15, 2010, the Company entered into a forward
setting interest rate contract with a notional amount of
$300.0 million and an effective date of December 8,
2010 whereby the Company will pay fixed interest and will
receive floating rate interest based on LIBOR on the effective
date of December 8, 2010. This swap was entered into in
anticipation of the expected issuance of at least
$300.0 million of new debt during the fourth quarter of
2010 and was designed to lock in the current market interest
rate as of April 15, 2010.
On June 9, 2010, the Company completed a private placement
of 81.0 million ($96.8 million) aggregate
principal amount of 2.58% Series 2010 Senior Notes due
June 9, 2015 (Senior Notes) pursuant to a
Master Note Purchase Agreement, dated June 9, 2010 (the
Purchase Agreement). The Purchase Agreement provides
for the issuance of additional series of notes in the future.
The Senior Notes bear interest at a rate of 2.58% per annum and
will mature on June 9, 2015. The Senior Notes are unsecured
obligations of the Company and rank pari passu in right of
payment with all of the Companys other senior debt. The
Company may at any time prepay all or any
12
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
portion of the Senior Notes; provided that such portion is
greater than 5% of the aggregate principal amount of Notes then
outstanding under the Purchase Agreement. In the event of a
prepayment, the Company will pay an amount equal to par plus
accrued interest plus a make-whole premium. The Purchase
Agreement contains certain covenants that restrict the
Companys ability to, among other things, transfer or sell
assets, create liens and engage in certain mergers or
consolidations. In addition, the Company must comply with a
leverage ratio and interest coverage ratio as set forth in the
Purchase Agreement. The Purchase Agreement provides for
customary events of default. In the case of an event of default
arising from specified events of bankruptcy or insolvency, all
outstanding Senior Notes will become due and payable immediately
without further action or notice. In the case of payment events
of defaults, any holder of the Senior Notes affected thereby may
declare all the Senior Notes held by it due and payable
immediately. In the case of any other event of default, a
majority of the holders of the Senior Notes may declare all the
Senior Notes to be due and payable immediately. The Company used
a portion of the proceeds from the private placement to pay down
existing debt outstanding under the Euro denominated Credit
Facility, with the remainder being available for ongoing
business activities.
11. | Derivative Instruments |
The Company enters into cash flow hedges to reduce the exposure
to variability in certain expected future cash flows. The type
of cash flow hedges the Company enters into includes foreign
currency contracts and interest rate exchange agreements that
effectively convert a portion of floating-rate debt to
fixed-rate debt and are designed to reduce the impact of
interest rate changes on future interest expense.
The effective portion of gains or losses on interest rate
exchange agreements is reported in accumulated other
comprehensive income in shareholders equity and
reclassified into net income in the same period or periods in
which the hedged transaction affects net income. The remaining
gain or loss in excess of the cumulative change in the present
value of future cash flows or the hedged item, if any, is
recognized into net income during the period of change.
Fair values relating to derivative financial instruments reflect
the estimated amounts that the Company would receive or pay to
sell or buy the contracts based on quoted market prices of
comparable contracts at each balance sheet date.
At September 30, 2010, the Company had three interest rate
exchange agreements. The first interest rate exchange agreement,
expiring in January 2011, effectively converted
$250.0 million of floating-rate debt into fixed-rate debt
at an interest rate of 3.25%. The second interest rate exchange
agreement, expiring in December 2011, with a current notional
amount of $90.0 million, effectively converted
$100.0 million of floating-rate debt into fixed-rate debt
at an interest rate of 4.00%. The fixed rate consists of the
fixed rate on the interest rate exchange agreements and the
Companys current margin of 40 basis points for the
Credit Facility and 80 basis points on the Term Loan. The
forward setting interest rate contract currently has a notional
amount of $300.0 million and an effective date of
December 8, 2010. The Company will pay fixed interest and
will receive floating rate interest based on LIBOR on the
effective date of December 8, 2010. This instrument was
entered into in anticipation of the expected issuance of at
least $300.0 million of new debt during the fourth quarter
of 2010 and was designed to lock in the current market interest
rate as of April 15, 2010.
Based on interest rates at September 30, 2010,
approximately $7.8 million of the amount included in
accumulated other comprehensive income in shareholders
equity at September 30, 2010 will be recognized to net
income over the next 12 months as the underlying hedged
transactions are realized.
At September 30, 2010, the Company had foreign currency
exchange contracts with an aggregate notional amount of
$4.0 million to manage its exposure to fluctuations in
foreign currency exchange rates. The change in fair market value
of these contracts for the nine months ended September 30,
2010 was immaterial.
13
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table sets forth the fair value amounts of
derivative instruments held by the Company as of
September 30, 2010 and December 31, 2009:
Fair Value-Liabilities | ||||||||||
September 30, |
December 31, |
|||||||||
2010 | 2009 | Balance Sheet Caption | ||||||||
(In thousands) | ||||||||||
Forward setting interest rate contract
|
$ | 42,189 | $ | | Accrued expenses | |||||
Interest rate exchange agreements
|
4,659 | 10,497 | Other noncurrent liabilities | |||||||
Foreign exchange contracts
|
133 | | Accounts receivable |
The following table summarizes the net change recognized and the
amounts and location of income (expense) and gain (loss)
reclassified into income for interest rate contracts and foreign
currency contracts as of September 30, 2010 and 2009:
Gain (Loss) |
||||||||||||||||||
Recognized in |
||||||||||||||||||
Other |
(Expense) |
|||||||||||||||||
Comprehensive |
and Gain |
|||||||||||||||||
Income | Reclassified into Income | |||||||||||||||||
Three Months Ended September 30, |
Income |
|||||||||||||||||
2010 | 2009 | 2010 | 2009 | Statement Caption | ||||||||||||||
(In thousands) | ||||||||||||||||||
Interest rate agreements
|
$ | (16,347 | ) | $ | (751 | ) | $ | (2,146 | ) | $ | (2,148 | ) | Interest expense | |||||
Foreign exchange contracts
|
93 | 112 | 36 | 346 | Sales |
Gain (Loss) |
||||||||||||||||||
Recognized in |
(Expense) |
|||||||||||||||||
Other |
and Gain |
|||||||||||||||||
Comprehensive |
Reclassified into |
|||||||||||||||||
Income | Income | |||||||||||||||||
Nine Months Ended September 30, |
Income |
|||||||||||||||||
2010 | 2009 | 2010 | 2009 | Statement Caption | ||||||||||||||
(In thousands) | ||||||||||||||||||
Interest rate agreements
|
$ | (43,102 | ) | $ | (943 | ) | $ | (6,751 | ) | $ | (5,757 | ) | Interest expense | |||||
Foreign exchange contracts
|
95 | 493 | 48 | 399 | Sales |
12. | Fair Value Measurements |
ASC 820 Fair Value Measurements and Disclosures
defines fair value, provides guidance for measuring fair value
and requires certain disclosures. This standard discusses
valuation techniques, such as the market approach (comparable
market prices), the income approach (present value of future
income or cash flow), and the cost approach (cost to replace the
service capacity of an asset or replacement cost). The standard
utilizes a fair value hierarchy that prioritizes the inputs to
valuation techniques used to measure fair value into three broad
levels. The following is a brief description of those three
levels:
| Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. | |
| Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. | |
| Level 3: Unobservable inputs that reflect the reporting entitys own assumptions. |
14
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table summarizes the basis used to measure the
Companys financial assets and liabilities at fair value on
a recurring basis in the balance sheet at September 30,
2010 and December 31, 2009:
Basis of Fair Value Measurements | ||||||||||||||||
Balance at |
||||||||||||||||
September 30, 2010 | Level 1 | Level 2 | Level 3 | |||||||||||||
(In thousands) | ||||||||||||||||
Money market investment
|
$ | 70,251 | $ | 70,251 | | | ||||||||||
Interest rate agreements
|
$ | 46,848 | | $ | 46,848 | | ||||||||||
Foreign currency contracts
|
$ | 133 | | $ | 133 | |
Basis of Fair Value Measurements | ||||||||||||||||
Balance at |
||||||||||||||||
December 31, 2009 | Level 1 | Level 2 | Level 3 | |||||||||||||
(In thousands) | ||||||||||||||||
Money market investment
|
$ | 9,186 | $ | 9,186 | | | ||||||||||
Interest rate agreements
|
$ | 10,497 | | $ | 10,497 | |
There were no transfers of assets or liabilities between
Level 1 and Level 2 during the first nine months of
2010.
In determining the fair value of the Companys interest
rate exchange agreement derivatives, the Company uses a present
value of expected cash flows based on market observable interest
rate yield curves commensurate with the term of each instrument
and the credit default swap market to reflect the credit risk of
either the Company or the counterparty.
The carrying value of our cash and cash equivalents, accounts
receivable, accounts payable and accrued expenses approximates
their fair values because of the short term nature of these
instruments. At September 30, 2010, the fair value of our
Credit Facility, Term Loan and Senior Notes, based on the
current market rates for debt with similar credit risk and
maturity, was approximately $478.8 million compared to the
carrying value of $485.1 million.
13. | Common and Preferred Stock |
At September 30, 2010 and December 31, 2009, the
Company had 150 million shares of authorized common stock,
with a par value of $.01 per share and 5 million shares of
preferred stock with a par value of $.01 per share. No preferred
stock was issued as of September 30, 2010 and
December 31, 2009.
14. | Share-Based Compensation |
During the nine months ending September 30, 2010, the
Company granted approximately 0.9 million stock options and
0.3 million unvested shares, respectively. During the nine
months ending September 30, 2009, the Company granted
approximately 1.2 million stock options and
0.3 million unvested shares, respectively.
15
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Total compensation cost for stock options is as follows:
Three Months |
Nine Months |
|||||||||||||||
Ended September 30, | Ended September 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
(In thousands) | ||||||||||||||||
Cost of goods sold
|
$ | 124 | $ | 220 | $ | 653 | $ | 758 | ||||||||
Selling, general and administrative expenses
|
1,402 | 1,455 | 5,265 | 5,109 | ||||||||||||
Total expense before income taxes
|
1,526 | 1,675 | 5,918 | 5,867 | ||||||||||||
Income tax benefit
|
(474 | ) | (531 | ) | (1,887 | ) | (1,889 | ) | ||||||||
Total expense after income taxes
|
$ | 1,052 | $ | 1,144 | $ | 4,031 | $ | 3,978 | ||||||||
Total compensation cost for unvested shares is as follows:
Three Months |
Nine Months |
|||||||||||||||
Ended September 30, | Ended September 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
(In thousands) | ||||||||||||||||
Cost of goods sold
|
$ | (42 | ) | $ | 63 | $ | 223 | $ | 187 | |||||||
Selling, general and administrative expenses
|
2,044 | 2,072 | 6,717 | 6,727 | ||||||||||||
Total expense before income taxes
|
2,002 | 2,135 | 6,940 | 6,914 | ||||||||||||
Income tax benefit
|
(398 | ) | (384 | ) | (1,448 | ) | (1,167 | ) | ||||||||
Total expense after income taxes
|
$ | 1,604 | $ | 1,751 | $ | 5,492 | $ | 5,747 | ||||||||
Classification of stock compensation cost within the
Consolidated Statements of Operations is consistent with
classification of cash compensation for the same employees and
$0.1 million of compensation cost was capitalized as part
of inventory.
As of September 30, 2010, there was $11.9 million of
total unrecognized compensation cost related to stock options
that is expected to be recognized over a weighted-average period
of 1.4 years, and $12.3 million of total unrecognized
compensation cost related to unvested shares that is expected to
be recognized over a weighted-average period of 1.0 years.
15. | Retirement Benefits |
The Company sponsors several qualified and nonqualified defined
benefit and defined contribution pension plans and other
postretirement plans for its employees. The following tables
provide the components of net periodic benefit cost for its
major defined benefit plans and its other postretirement plans.
Pension Benefits | ||||||||||||||||
Three Months Ended September 30, | ||||||||||||||||
2010 | 2009 | |||||||||||||||
U.S. | Non-U.S. | U.S. | Non-U.S. | |||||||||||||
(In thousands) | ||||||||||||||||
Service cost
|
$ | 311 | $ | 173 | $ | 388 | $ | 214 | ||||||||
Interest cost
|
1,114 | 519 | 1,093 | 549 | ||||||||||||
Expected return on plan assets
|
(1,081 | ) | (80 | ) | (876 | ) | (205 | ) | ||||||||
Net amortization
|
1,047 | 72 | 1,218 | 96 | ||||||||||||
Net periodic benefit cost
|
$ | 1,391 | $ | 684 | $ | 1,823 | $ | 654 | ||||||||
16
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Pension Benefits | ||||||||||||||||
Nine Months Ended September 30, | ||||||||||||||||
2010 | 2009 | |||||||||||||||
U.S. | Non-U.S. | U.S. | Non-U.S. | |||||||||||||
(In thousands) | ||||||||||||||||
Service cost
|
$ | 1,249 | $ | 357 | $ | 1,164 | $ | 609 | ||||||||
Interest cost
|
3,393 | 1,071 | 3,281 | 1,562 | ||||||||||||
Expected return on plan assets
|
(3,297 | ) | (163 | ) | (2,629 | ) | (577 | ) | ||||||||
Net amortization
|
3,301 | 148 | 3,654 | 273 | ||||||||||||
Net periodic benefit cost
|
$ | 4,646 | $ | 1,413 | $ | 5,470 | $ | 1,867 | ||||||||
Other Postretirement Benefits | ||||||||||||||||
Three Months |
Nine Months |
|||||||||||||||
Ended September 30, | Ended September 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
(In thousands) | ||||||||||||||||
Service cost
|
$ | 130 | $ | 149 | $ | 390 | $ | 441 | ||||||||
Interest cost
|
259 | 343 | 778 | 1,017 | ||||||||||||
Net amortization
|
(87 | ) | 23 | (262 | ) | 47 | ||||||||||
Net periodic benefit cost
|
$ | 302 | $ | 515 | $ | 906 | $ | 1,505 | ||||||||
The Company previously disclosed in its financial statements for
the year ended December 31, 2009, that it expected to
contribute approximately $4.7 million to these pension
plans and $1.0 million to its other postretirement benefit
plans in 2010. As of September 30, 2010, $3.3 million
of contributions have been made to the pension plans and
$0.7 million have been made to its other postretirement
benefit plans. The Company presently anticipates contributing up
to an additional $1.7 million in 2010 to fund these pension
plans and other postretirement benefit plans.
In March of 2010 the United States enacted two new laws relating
to healthcare. The enactment of the Patient Protection and
Affordable Care Act and the Health Care and Education
Reconciliation Act of 2010 has resulted in comprehensive health
care reform. The effect of this new legislation is not expected
to have a material impact on the consolidated financial
position, results of operations or cash flows of the Company.
16. | Legal Proceedings |
The Company is party to various legal proceedings arising in the
ordinary course of business, none of which are expected to have
a material adverse effect on its business, financial condition,
results of operations or cash flows.
17. | Income Taxes |
The Companys provision for income taxes is based upon
estimated annual tax rates for the year applied to federal,
state and foreign income. The provision for income taxes
increased to $18.6 million in the third quarter of 2010
from $14.2 million in the third quarter of 2009. The
effective tax rate increased to 32.6% for the third quarter of
2010 compared to 32.2% in the third quarter of 2009 due to the
mix of global pre-tax income among jurisdictions.
The provision for income taxes increased to $55.7 million
in the first nine months of 2010 from $39.7 million in the
same period of 2009. The effective tax rate decreased to 32.5%
for the first nine months of 2010 compared to 33.1% in the same
period of 2009 primarily due to the mix of global pre-tax income
among jurisdictions.
The Company and its subsidiaries file income tax returns in the
U.S. federal jurisdiction, and various state and foreign
jurisdictions. Due to the potential for resolution of federal,
state and foreign examinations, and the
17
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
expiration of various statutes of limitation, it is reasonably
possible that the Companys gross unrecognized tax benefits
balance may change within the next twelve months by a range of
zero to $1.7 million.
18. | Comprehensive Income |
The components of comprehensive income (loss) are as follows:
Three Months |
Nine Months |
|||||||||||||||
Ended September 30, | Ended September 30, | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
(In thousands) | ||||||||||||||||
Net income
|
$ | 38,564 | $ | 29,777 | $ | 115,587 | $ | 80,304 | ||||||||
Other comprehensive income:
|
||||||||||||||||
Unrealized losses on derivatives, net of tax
|
(9,080 | ) | (639 | ) | (23,076 | ) | (450 | ) | ||||||||
Pension and other post-retirement plans, net of tax
|
(12 | ) | 4 | 728 | 1,702 | |||||||||||
Cumulative translation adjustment
|
38,678 | 11,224 | (12,187 | ) | 23,558 | |||||||||||
Comprehensive income
|
$ | 68,150 | $ | 40,366 | $ | 81,052 | $ | 105,114 | ||||||||
Foreign currency translation adjustments are generally not
adjusted for income taxes as they relate to indefinite
investments in non-US subsidiaries.
19. | Subsequent Events |
On November 1, 2010, the Company acquired The Fitzpatrick
Company (Fitzpatrick) for cash consideration of
approximately $21.0 million. Fitzpatrick is a global leader
in the design and manufacture of process technologies for the
pharmaceutical, food and personal care markets. Fitzpatrick
designs and manufactures customized size reduction, roll
compaction and drying systems to support their customers
product development and manufacturing processes. Fitzpatrick
will expand the capability of IDEXs Quadro Engineering by
adding coarse particle sizing, roll compaction and drying
systems to Quadros fine particle processing. Headquartered
in Elmhurst, Illinois, Fitzpatrick has annual revenues of
approximately $22.0 million. Fitzpatrick will operate in
the Chemical Food & Pharmaceutical Group within the
Fluid and Metering Technologies segment.
18
Table of Contents
Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations. |
Cautionary
Statement Under the Private Securities Litigation Reform
Act
The Historical Overview and the Liquidity and
Capital Resources sections of this managements
discussion and analysis of our financial condition and results
of operations contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Exchange Act of 1934, as
amended. These statements may relate to, among other things,
operating results and are indicated by words or phrases such as
expects, should, will, and
similar words or phrases. These statements are subject to
inherent uncertainties and risks that could cause actual results
to differ materially from those anticipated at the date of this
filing. The risks and uncertainties include, but are not limited
to, IDEX Corporations (IDEX or the
Company) ability to integrate and operate acquired
businesses on a profitable basis and other risks and
uncertainties identified under the heading Risk
Factors included in item 1A of the Companys
Annual Report on
Form 10-K
for the year ended December 31, 2009 and information
contained in subsequent periodic reports filed by IDEX with the
Securities and Exchange Commission. Investors are cautioned not
to rely unduly on forward-looking statements when evaluating the
information presented here.
Historical
Overview
IDEX Corporation is an applied solutions company specializing in
fluid and metering technologies, health and science
technologies, dispensing equipment, and fire, safety and other
diversified products built to its customers
specifications. Our products are sold in niche markets to a wide
range of industries throughout the world. Accordingly, our
businesses are affected by levels of industrial activity and
economic conditions in the U.S. and in other countries
where we do business and by the relationship of the
U.S. dollar to other currencies. Levels of capacity
utilization and capital spending in certain industries and
overall industrial activity are among the factors that influence
the demand for our products.
The Company consists of four reportable segments:
Fluid & Metering Technologies, Health &
Science Technologies, Dispensing Equipment and Fire &
Safety/Diversified Products.
The Fluid & Metering Technologies Segment designs,
produces and distributes positive displacement pumps, flow
meters, injectors, and other fluid-handling pump modules and
systems and provides flow monitoring and other services for
water and wastewater. The Health & Science
Technologies Segment designs, produces and distributes a wide
range of precision fluidics solutions, including very high
precision, low-flow rate pumping solutions required in
analytical instrumentation, clinical diagnostics and drug
discovery, high performance molded and extruded biocompatible
medical devices and implantables, air compressors used in
medical, dental and industrial applications, and precision gear
and peristaltic pump technologies that meet exacting OEM
specifications. The Dispensing Equipment Segment produces
precision equipment for dispensing, metering and mixing
colorants, paints, and hair colorants and other personal care
products used in a variety of retail and commercial businesses
around the world. The Fire & Safety/Diversified
Products Segment produces firefighting pumps and controls,
rescue tools, lifting bags and other components and systems for
the fire and rescue industry, and engineered stainless steel
banding and clamping devices used in a variety of industrial and
commercial applications
Results
of Operations
The following is a discussion and analysis of our financial
position and results of operations for the periods ended
September 30, 2010 and 2009. For purposes of this
discussion and analysis section, reference is made to the table
below and the Companys Condensed Consolidated Statements
of Operations included in Item 1.
Performance
in the Three Months Ended September 30, 2010 Compared with
the Same Period of 2009
Sales in the three months ended September 30, 2010 were
$373.7 million, a 16% increase from the comparable period
last year. This increase reflects a 14% increase in organic
sales and 4% from acquisition (Seals April 2010 and
OBL July 2010), partially offset by 2% from
unfavorable foreign currency translation. Sales to international
customers represented approximately 50% of total sales in the
current period compared to 48% in the same period in 2009.
19
Table of Contents
For the third quarter of 2010, Fluid & Metering
Technologies contributed 47 percent of sales and
43 percent of operating income; Health & Science
Technologies accounted for 28 percent of sales and
30 percent of operating income; Dispensing Equipment
accounted for 7 percent of sales and 4 percent of
operating income; and Fire & Safety/Diversified
Products represented 18 percent of sales and
23 percent of operating income.
Fluid & Metering Technologies sales of
$176.9 million for the three months ended
September 30, 2010 increased $19.9 million, or 13%
compared with 2009, reflecting a 14% increase in organic growth,
1% from acquisition (OBL July 2010) and 2%
unfavorable foreign currency translation. The increase in
organic growth was driven by strong global growth in chemical,
food, pharma and water and waste water markets. In the third
quarter of 2010, organic sales increased approximately 17%
domestically and 11% internationally. Organic business sales to
customers outside the U.S. were approximately 46% of total
segment sales during the third quarter of 2010 and 41% in 2009.
Health & Science Technologies sales of
$104.3 million increased $28.2 million, or 37% in the
third quarter of 2010 compared with 2009. This reflects a 24%
increase in organic growth and 14% from acquisition
(Seals April 2010), partially offset by 1% from
unfavorable foreign currency translation. The increase in
organic growth reflects market strength across all
Health & Science Technologies products. In the third
quarter of 2010, organic sales increased 20% domestically and
30% internationally. Organic business sales to customers outside
the U.S. were approximately 43% of total segment sales in
the third quarter of 2010, compared to 46% in 2009.
Dispensing Equipment sales of $26.5 million increased
$0.9 million, or 4% in the third quarter of 2010 compared
with 2009. This increase reflects 9% from organic sales,
partially offset by 5% unfavorable foreign currency translation.
The increase in organic growth is due to strength in Asia and
parts of Eastern Europe, partially offset by market softness in
North America and Western Europe. In the third quarter of 2010,
organic sales increased 22% domestically and 5% internationally.
Organic sales to customers outside the U.S. were
approximately 74% of total segment sales in the third quarter of
2010, compared with 78% in the comparable quarter of 2009.
Fire & Safety/Diversified Products sales of
$67.0 million increased $1.5 million, or 2% in the
third quarter of 2010 compared with 2009. This change reflects a
6% increase in organic business volume, partially offset by 4%
unfavorable foreign currency translation. The change in organic
business reflects strength in rescue equipment and engineered
band clamping systems, partially offset by weakness in fire
suppression. In the third quarter of 2010, organic business
sales decreased 1% domestically and increased 12%
internationally. Organic sales to customers outside the
U.S. were approximately 56% of total segment sales in the
third quarter of 2010, compared to 55% in 2009.
20
Table of Contents
Three Months |
Nine Months |
|||||||||||||||
Ended September 30,(1) | Ended September 30,(1) | |||||||||||||||
2010 | 2009 | 2010 | 2009 | |||||||||||||
Fluid & Metering Technologies
|
||||||||||||||||
Net sales
|
$ | 176,881 | $ | 156,939 | $ | 524,306 | $ | 470,957 | ||||||||
Operating
income(2)
|
31,554 | 25,755 | 93,928 | 70,731 | ||||||||||||
Operating margin
|
17.8 | % | 16.4 | % | 17.9 | % | 15.0 | % | ||||||||
Depreciation and amortization
|
$ | 8,335 | $ | 8,061 | $ | 24,560 | $ | 24,396 | ||||||||
Capital expenditures
|
3,359 | 3,810 | 13,030 | 9,682 | ||||||||||||
Health & Science Technologies
|
||||||||||||||||
Net sales
|
$ | 104,319 | $ | 76,138 | $ | 292,327 | $ | 224,142 | ||||||||
Operating
income(2)
|
21,661 | 14,287 | 60,649 | 34,703 | ||||||||||||
Operating margin
|
20.8 | % | 18.8 | % | 20.7 | % | 15.5 | % | ||||||||
Depreciation and amortization
|
$ | 4,640 | $ | 3,866 | $ | 12,519 | $ | 10,579 | ||||||||
Capital expenditures
|
2,295 | 1,879 | 6,059 | 3,793 | ||||||||||||
Dispensing Equipment
|
||||||||||||||||
Net sales
|
$ | 26,480 | $ | 25,580 | $ | 101,169 | $ | 104,111 | ||||||||
Operating income
(loss)(2)
|
2,711 | (311 | ) | 19,062 | 13,112 | |||||||||||
Operating margin
|
10.2 | % | (1.2 | )% | 18.8 | % | 12.6 | % | ||||||||
Depreciation and amortization
|
$ | 816 | $ | 670 | $ | 2,980 | $ | 2,340 | ||||||||
Capital expenditures
|
245 | 292 | 887 | 850 | ||||||||||||
Fire & Safety/Diversified Products
|
||||||||||||||||
Net sales
|
$ | 66,993 | $ | 65,524 | $ | 194,385 | $ | 192,633 | ||||||||
Operating
income(2)
|
17,045 | 15,932 | 44,032 | 42,790 | ||||||||||||
Operating margin
|
25.4 | % | 24.3 | % | 22.7 | % | 22.2 | % | ||||||||
Depreciation and amortization
|
$ | 1,195 | $ | 1,287 | $ | 3,993 | $ | 3,815 | ||||||||
Capital expenditures
|
786 | 853 | 2,662 | 2,569 | ||||||||||||
Company
|
||||||||||||||||
Net sales
|
$ | 373,731 | $ | 323,249 | $ | 1,107,855 | $ | 986,317 | ||||||||
Operating
income(2)
|
62,439 | 46,517 | 183,112 | 132,413 | ||||||||||||
Operating margin
|
16.7 | % | 14.4 | % | 16.5 | % | 13.4 | % | ||||||||
Depreciation and
amortization(3)
|
$ | 15,235 | $ | 14,135 | $ | 44,888 | $ | 41,893 | ||||||||
Capital expenditures
|
7,936 | 7,081 | 25,972 | 18,303 |
(1) | Data includes acquisitions of OBL (July 2010) in the Fluid & Metering Technologies Group and Seals (April 2010) in the Health & Science Technologies Group from the date of acquisition. | |
(2) | Segment operating income excludes unallocated corporate operating expenses. | |
(3) | Excludes amortization of debt issuance expenses. |
Gross profit of $154.1 million in the third quarter of 2010
increased $25.1 million, or 19% from 2009. Gross profit as
a percent of sales was 41.2% in the third quarter of 2010 and
39.9% in 2009. The increase in gross margin primarily reflects
higher sales volume and change in product mix.
Selling, general and administrative (SG&A)
expenses increased to $88.2 million in the third quarter of
2010 from $79.8 million in 2009. The $8.4 million
increase reflects approximately $4.9 million for volume
related expenses and $3.5 million for incremental costs
associated with the acquisitions of Seals in April 2010 and OBL
in July 2010. As a percent of sales, SG&A expenses were
23.6% for 2010 and 24.7% for 2009.
21
Table of Contents
During the three months ended September 30, 2010, the
Company recorded pre-tax restructuring expenses totaling
$3.5 million, while $2.8 million was recorded for the
same period in 2009. These restructuring expenses were mainly
attributable to employee severance related to employee
reductions across various functional areas and facility closures
resulting from the Companys cost savings initiatives.
Operating income of $62.4 million and operating margins of
16.7% in the third quarter of 2010 were up from the
$46.5 million and 14.4% recorded in 2009, primarily
reflecting an increase in volume and cost reductions due to our
restructuring initiatives. In the Fluid & Metering
Technologies Segment, operating income of $31.6 million and
operating margins of 17.8% in the third quarter of 2010 were up
from the $25.8 million and 16.4% recorded in 2009,
principally due to higher sales and cost reduction initiatives.
In the Health & Science Technologies Segment,
operating income of $21.7 million and operating margins of
20.8% in the third quarter of 2010 were up from the
$14.3 million and 18.8% recorded in 2009 due to higher
volume and cost reduction initiatives. In the Dispensing
Equipment Segment, operating income of $2.7 million and
operating margins of 10.2% in the third quarter of 2010 were up
from the $0.3 million of operating loss and (1.2)% recorded
in 2009 due to volume, cost reduction initiatives and improved
productivity. Operating income and operating margins in the
Fire & Safety/Diversified Products Segment of
$17.0 million and 25.4%, respectively, were higher than the
$15.9 million and 24.3% recorded in 2009 due to higher
sales and favorable mix.
Other expense of $1.1 million in 2010 was unfavorable
compared with the $1.4 million gain in 2009, due to
unfavorable foreign currency translation.
Interest expense increased slightly to $4.2 million in 2010
from $4.0 million in 2009.
The provision for income taxes is based upon estimated annual
tax rates for the year applied to federal, state and foreign
income. The provision for income taxes increased to
$18.6 million in the third quarter of 2010 compared to the
third quarter of 2009, which was $14.2 million. The
effective tax rate increased to 32.6% for the third quarter of
2010 compared to 32.2% in the third quarter of 2009 due to the
mix of global pre-tax income among jurisdictions.
Net income for the current quarter of $38.6 million
increased from the $29.8 million earned in the third
quarter of 2009. Diluted earnings per share in the third quarter
of 2010 of $0.47 increased $0.10, or 28%, compared with the
third quarter of 2009.
Performance
in the Nine Months Ended September 30, 2010 Compared with
the Same Period of 2009
Sales in the nine months ended September 30, 2010 were
$1,107.9 million, a 12% increase from the comparable period
last year. This increase reflects a 10% increase in organic
sales and 2% from acquisition (Seals April 2010 and
OBL July 2010). Sales to international customers
represented approximately 48% of total sales in the current
period compared to 46% in the same period in 2009.
For the first nine months of 2010, Fluid & Metering
Technologies contributed 47 percent of sales and
43 percent of operating income; Health & Science
Technologies accounted for 26 percent of sales and
28 percent of operating income; Dispensing Equipment
accounted for 9 percent of sales and 9 percent of
operating income; and Fire & Safety/Diversified
Products represented 18 percent of sales and
20 percent of operating income.
Fluid & Metering Technologies sales of
$524.3 million for the nine months ended September 30,
2010 increased $53.3 million, or 11% compared with 2009,
reflecting an 11% increase in organic growth. The increase in
organic growth was driven by strong global growth across
chemical, food, pharma and water and waste water markets. In the
first nine months of 2010, organic sales increased approximately
13% domestically and 10% internationally. Organic business sales
to customers outside the U.S. were approximately 45% of
total segment sales during the first nine months of 2010 and 40%
in 2009.
Health & Science Technologies sales of
$292.3 million increased $68.2 million, or 30% in the
first nine months of 2010 compared with 2009. This reflects a
22% increase in organic growth and 8% from acquisition
(Seals April 2010). The increase in organic growth
reflects market strength across all Health & Science
Technologies products. In the first nine months of 2010, organic
sales increased 18% domestically and 30% internationally.
Organic business sales to customers outside the U.S. were
approximately 41% of total segment sales in the first nine
months of 2010, compared to 40% in 2009.
22
Table of Contents
Dispensing Equipment sales of $101.2 million decreased
$2.9 million, or 3% in the first nine months of 2010
compared with 2009. This reflects a 2% decrease in organic
growth and 1% unfavorable foreign currency translation. The
decrease in organic growth is due to market softness in North
America. In the first nine months of 2010, organic sales
decreased 13% domestically and increased 5% internationally.
Organic sales to customers outside the U.S. were
approximately 66% of total segment sales in the first nine
months of 2010, compared with 64% in the comparable period of
2009.
Fire & Safety/Diversified Products sales of
$194.4 million increased $1.8 million, or 1% in the
first nine months of 2010 compared with 2009. This reflects a 2%
increase in organic growth, partially offset by 1% unfavorable
foreign currency translation. The change in organic business
reflects strength in engineered band clamping systems, partially
offset by weakness in fire suppression. In the first nine months
of 2010, organic business sales decreased 5% domestically and
increased 8% internationally. Organic sales to customers outside
the U.S. were approximately 55% of total segment sales in
the first nine months of both 2010 and 2009.
Gross profit of $456.5 million in the first nine months of
2010 increased $73.1 million, or 19% from 2009. Gross
profit as a percent of sales was 41.2% in the first nine months
of 2010 and 38.9% in 2009. The increase in gross margin
primarily reflects higher sales volume and change in product mix.
SG&A expenses increased to $267.0 million in the first
nine months of 2010 from $242.7 million in 2009. The
$24.3 million increase reflects approximately
$18.8 million for volume related expenses and
$5.5 million for incremental costs associated with the
acquisitions of Seals in April 2010 and OBL in July 2010. As a
percent of sales, SG&A expenses were 24.1% for 2010 and
24.6% for 2009.
During the nine months ended September 30, 2010, the
Company recorded pre-tax restructuring expenses totaling
$6.4 million, while $8.3 million was recorded for the
same period in 2009. These restructuring expenses were mainly
attributable to employee severance related to employee
reductions across various functional areas and facility closures
resulting from the Companys cost savings initiatives.
Operating income of $183.1 million and operating margins of
16.5% in the first nine months of 2010 were up from the
$132.4 million and 13.4% recorded in 2009, primarily
reflecting an increase in volume and cost reductions due to our
restructuring initiatives. In the Fluid & Metering
Technologies Segment, operating income of $93.9 million and
operating margins of 17.9% in the first nine months of 2010 were
up from the $70.7 million and 15.0% recorded in 2009
principally due to higher sales and cost reduction initiatives.
In the Health & Science Technologies Segment,
operating income of $60.6 million and operating margins of
20.7% in the first nine months of 2010 were up from the
$34.7 million and 15.5% recorded in 2009 due to higher
volume and cost reduction initiatives. In the Dispensing
Equipment Segment, operating income of $19.1 million and
operating margins of 18.8% in the first nine months of 2010 were
up from the $13.1 million and 12.6% recorded in 2009, due
to cost reduction initiatives and improved productivity.
Operating income and operating margin in the Fire &
Safety/Diversified Products Segment of $44.0 million and
22.7% were up from the $42.8 million and 22.2% recorded in
2009 due to higher sales and favorable mix.
Other expense of $0.6 million in 2010 was unfavorable
compared with the $0.8 million gain in 2009, primarily due
to unfavorable foreign currency translation.
Interest expense decreased to $11.2 million in 2010 from
$13.2 million in 2009. The decrease was principally due to
lower debt levels and a lower interest rate environment.
The provision for income taxes is based upon estimated annual
tax rates for the year applied to federal, state and foreign
income. The provision for income taxes increased to
$55.7 million for the first nine months of 2010 compared to
the same period in 2009, which was $39.7 million. The
effective tax rate decreased to 32.5% for the first nine months
of 2010 compared to 33.1% in the same period of 2009 due to the
mix of global pre-tax income among jurisdictions.
Net income for the current period of $115.6 million
increased from the $80.3 million earned in the first nine
months of 2009. Diluted earnings per share in the first nine
months of 2010 of $1.40 increased $0.41, or 41%, compared with
the first nine months of 2009.
23
Table of Contents
Liquidity
and Capital Resources
At September 30, 2010, working capital was
$380.1 million and our current ratio was 2.4 to 1. Cash
flows from operating activities of $157.3 million were flat
compared to the same period in 2009.
Cash flows provided by operations were more than adequate to
fund capital expenditures of $26.0 million and
$18.3 million in the first nine months of 2010 and 2009,
respectively. Capital expenditures were generally for machinery
and equipment that improved productivity and tooling to support
the global sourcing initiatives, although a portion was for
business system technology and replacement of equipment and
facilities. Management believes that the Company has ample
capacity in its plants and equipment to meet expected needs for
future growth in the intermediate term.
The Company acquired Seals in April 2010 for cash consideration
of $51.3 million and the assumption of approximately
$2.7 million in debt related items, OBL in July 2010 for
cash consideration of $12.8 million and approximately $2.6
in cash to be paid in the fourth quarter and Periflo in
September 2010 for cash consideration of $4.2 million. The
cash payment for Seals was financed by borrowings under the
Companys credit facility.
The Company maintains a $600.0 million unsecured domestic,
multi-currency bank revolving Credit Facility, which expires on
December 21, 2011. At September 30, 2010 there was
$284.9 million outstanding under the Credit Facility. The
net available borrowing under the Credit Facility as of
September 30, 2010, was approximately $315.1 million.
Interest is payable quarterly on the outstanding borrowings at
the bank agents reference rate. Interest on borrowings
based on LIBOR plus an applicable margin is payable on the
maturity date of the borrowing, or quarterly from the effective
date for borrowings exceeding three months. The applicable
margin is based on the Companys senior, unsecured,
long-term debt rating and can range from 24 basis points to
50 basis points. Based on the Companys credit rating
at September 30, 2010, the applicable margin was
40 basis points. An annual Credit Facility fee, also based
on the Companys credit rating, is currently 10 basis
points and is payable quarterly.
At September 30, 2010 the Company has one interest rate
exchange agreement related to the Credit Facility. The interest
rate exchange agreement, expiring in January 2011, effectively
converted $250.0 million of floating-rate debt into
fixed-rate debt at an interest rate of 3.25%. The fixed rate
noted above consists of the fixed rate on the interest rate
exchange agreement and the Companys current margin of
40 basis points on the Credit Facility.
On April 18, 2008, the Company completed a
$100.0 million unsecured senior bank term loan agreement
(Term Loan), with covenants consistent with the
existing Credit Facility and a maturity on December 21,
2011. At September 30, 2010, there was $90.0 million
outstanding under the Term Loan with $7.5 million included
within short term borrowings. Interest under the Term Loan is
based on the bank agents reference rate or LIBOR plus an
applicable margin and is payable at the end of the selected
interest period, but at least quarterly. The applicable margin
is based on the Companys senior, unsecured, long-term debt
rating and can range from 45 to 100 basis points. Based on
the Companys current debt rating, the applicable margin is
80 basis points. The Term Loan requires a repayment of
$7.5 million in April 2011, with the remaining balance due
on December 21, 2011. The Company used the proceeds from
the Term Loan to pay down existing debt outstanding under the
Credit Facility. At September 30, 2010 the Company has an
interest rate exchange agreement related to the Term Loan that
expires in December 2011. With a current notional amount of
$90.0 million, the agreement effectively converted
$100.0 million of floating-rate debt into fixed-rate debt
at an interest rate of 4.00%. The fixed rate consists of the
fixed rate on the interest rate exchange agreement and the
Companys current margin of 80 basis points on the
Term Loan.
On April 15, 2010, the Company entered into a forward
setting interest rate contract with a notional amount of
$300.0 million and an effective date of December 8,
2010 whereby the Company will pay fixed interest and will
receive floating rate interest based on LIBOR on the effective
date of December 8, 2010. This instrument was entered into
in anticipation of the expected issuance of at least
$300.0 million of new debt during the fourth quarter of
2010 and was designed to lock in the current market interest
rate as of April 15, 2010.
On June 9, 2010, the Company completed a private placement
of 81.0 million ($96.8 million) aggregate
principal amount of 2.58% Series 2010 Senior Notes due
June 9, 2015 (Senior Notes) pursuant to a
Master Note Purchase Agreement, dated June 9, 2010 (the
Purchase Agreement). The Purchase Agreement provides
for the issuance of additional series of notes in the future.
The Senior Notes bear interest at a rate of 2.58% per annum and
24
Table of Contents
will mature on June 9, 2015. The Senior Notes are unsecured
obligations of the Company and rank pari passu in right of
payment with all of the Companys other senior debt. The
Company may at any time prepay all or any portion of the Senior
Notes; provided that such portion is greater than 5% of the
aggregate principal amount of the Senior Notes then outstanding
under the Purchase Agreement. In the event of a prepayment, the
Company will pay an amount equal to par plus accrued interest
plus a make-whole premium. The Purchase Agreement contains
certain covenants that restrict the Companys ability to,
among other things, transfer or sell assets, create liens and
engage in certain mergers or consolidations. In addition, the
Company must comply with a leverage ratio and interest coverage
ratio as set forth in the Purchase Agreement. The Purchase
Agreement provides for customary events of default. In the case
of an event of default arising from specified events of
bankruptcy or insolvency, all outstanding Senior Notes will
become due and payable immediately without further action or
notice. In the case of payment events of defaults, any holder of
the Senior Notes affected thereby may declare all the Senior
Notes held by it due and payable immediately. In the case of any
other event of default, a majority of the holders of the Senior
Notes may declare all the Senior Notes to be due and payable
immediately. The Company used a portion of the proceeds from the
private placement to pay down existing debt outstanding under
the Euro denominated Credit Facility, with the remainder being
available for ongoing business activities.
We believe for the next 12 months that cash flow from
operations and our availability under the Credit Facility will
be sufficient to meet our operating requirements, interest on
all borrowings, required debt repayments, any authorized share
repurchases, planned capital expenditures, and annual dividend
payments to holders of common stock. In the event that suitable
businesses are available for acquisition upon terms acceptable
to the Board of Directors, we may obtain all or a portion of the
financing for the acquisitions through the incurrence of
additional long-term borrowings.
Item 3. | Quantitative and Qualitative Disclosures About Market Risk. |
The Company is subject to market risk associated with changes in
foreign currency exchange rates and interest rates. We may, from
time to time, enter into foreign currency forward contracts and
interest rate swaps on our debt when we believe there is a
financial advantage in doing so. A treasury risk management
policy, adopted by the Board of Directors, describes the
procedures and controls over derivative financial and commodity
instruments, including foreign currency forward contracts and
interest rate swaps. Under the policy, we do not use derivative
financial or commodity instruments for trading purposes, and the
use of these instruments is subject to strict approvals by
senior officers. Typically, the use of derivative instruments is
limited to foreign currency forward contracts and interest rate
swaps on the Companys outstanding long-term debt. The
Companys exposure related to derivative instruments
primarily relates to the forward setting interest rate contract,
a 25-basis point movement in the ten year U.S. treasury
yield would result in an approximate $7.0 million change in
the value of the forward setting interest rate contract.
The Companys foreign currency exchange rate risk is
limited principally to the Euro, British Pound, Canadian Dollar
and Chinese Renminbi. We manage our foreign exchange risk
principally through invoicing our customers in the same currency
as the source of our products. The effect of transaction gains
and losses is reported within Other income
(expense)-net on the Condensed Consolidated Statements of
Operations.
The Companys interest rate exposure is primarily related
to the $491.6 million of total debt outstanding at
September 30, 2010. Approximately 8% of the debt is priced
at interest rates that float with the market. A 50-basis point
movement in the interest rate on the floating rate debt would
result in an approximate $0.2 million annualized increase
or decrease in interest expense and cash flows. The remaining
debt is fixed rate debt.
Item 4. | Controls and Procedures. |
The Company maintains disclosure controls and procedures that
are designed to ensure that information required to be disclosed
in the Companys Exchange Act reports is recorded,
processed, summarized and reported within the time periods
specified in the SECs rules and forms, and that such
information is accumulated and communicated to the
Companys management, including its Chief Executive Officer
and Chief Financial Officer, as appropriate, to allow timely
decisions regarding required disclosure. In designing and
evaluating the disclosure controls and procedures, management
recognized that any controls and procedures, no matter how well
designed
25
Table of Contents
and operated, can provide only reasonable assurance of achieving
the desired control objectives, and management is required to
apply its judgment in evaluating the cost-benefit relationship
of possible controls and procedures.
As required by SEC
Rule 13a-15(b),
the Company carried out an evaluation, under the supervision and
with the participation of the Companys management,
including the Companys Chief Executive Officer and the
Companys Chief Financial Officer, of the effectiveness of
the design and operation of the Companys disclosure
controls and procedures as of the end of the period covered by
this report. Based on the foregoing, the Companys Chief
Executive Officer and Chief Financial Officer concluded as of
September 30, 2010 that the Companys disclosure
controls and procedures were effective.
There has been no change in the Companys internal controls
over financial reporting during the Companys most recent
fiscal quarter that has materially affected, or is reasonably
likely to materially affect, the Companys internal
controls over financial reporting.
During the first nine months of 2010, the Company implemented a
new ERP system at one of our larger business units. The Company
believes that effective internal control over financial
reporting was maintained during and after this conversion.
PART II.
OTHER INFORMATION
Item 1. | Legal Proceedings. |
The Company and six of its subsidiaries are presently named as
defendants in a number of lawsuits claiming various
asbestos-related personal injuries, allegedly as a result of
exposure to products manufactured with components that contained
asbestos. Such components were acquired from third party
suppliers, and were not manufactured by any of the subsidiaries.
To date, the majority of the Companys settlements and
legal costs, except for costs of coordination, administration,
insurance investigation and a portion of defense costs, have
been covered in full by insurance subject to applicable
deductibles. However, the Company cannot predict whether and to
what extent insurance will be available to continue to cover
such settlements and legal costs, or how insurers may respond to
claims that are tendered to them.
Claims have been filed in jurisdictions throughout the United
States. Most of the claims resolved to date have been dismissed
without payment. The balance have been settled for various
insignificant amounts. Only one case has been tried, resulting
in a verdict for the Companys business unit.
No provision has been made in the financial statements of the
Company, other than for insurance deductibles in the ordinary
course, and the Company does not currently believe the
asbestos-related claims will have a material adverse effect on
the Companys business, financial position, results of
operations or cash flows.
The Company is also party to various other legal proceedings
arising in the ordinary course of business, none of which is
expected to have a material adverse effect on its business,
financial condition, results of operations or cash flows.
26
Table of Contents
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds. |
Total Number of |
Maximum Dollar |
|||||||||||||||
Shares Purchased as |
Value that May Yet |
|||||||||||||||
Part of Publicly |
be Purchased |
|||||||||||||||
Total Number of |
Average Price |
Announced Plans |
Under the Plans |
|||||||||||||
Period | Shares Purchased | Paid per Share | or Programs(1) | or Programs(1) | ||||||||||||
July 1, 2010 to July 31, 2010 |
| | | $ | 75,000,020 | |||||||||||
August 1, 2010 to August 31, 2010 |
| | | $ | 75,000,020 | |||||||||||
September 1, 2010 to September 30, 2010 |
| | | $ | 75,000,020 | |||||||||||
Total
|
| | | $ | 75,000,020 | |||||||||||
(1) | On April 21, 2008, IDEXs Board of Directors authorized the repurchase of up to $125.0 million of its outstanding common shares either in the open market or through private transactions. |
Item 5. | Other Information. |
There has been no material change to the procedures by which
security holders may recommend nominees to the Companys
board.
Item 6. | Exhibits. |
The exhibits listed in the accompanying
Exhibit Index are filed as part of this report.
27
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
IDEX Corporation
/s/ Dominic
A. Romeo
Dominic A. Romeo
Vice President and Chief Financial Officer
(duly authorized principal financial officer)
/s/ Michael
J. Yates
Michael J. Yates
Vice President and Chief Accounting Officer
(duly authorized principal accounting officer)
November 3, 2010
28
Table of Contents
EXHIBIT INDEX
Exhibit |
||||
Number | Description | |||
3 | .1 | Restated Certificate of Incorporation of IDEX Corporation (formerly HI, Inc.) (incorporated by reference to Exhibit No. 3.1 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on April 21, 1988) | ||
3 | .1(a) | Amendment to Restated Certificate of Incorporation of IDEX Corporation (formerly HI, Inc.), (incorporated by reference to Exhibit No. 3.1(a) to the Quarterly Report of IDEX on Form 10-Q for the quarter ended March 31, 1996, Commission File No. 1-10235) | ||
3 | .1(b) | Amendment to Restated Certificate of Incorporation of IDEX Corporation (incorporated by reference to Exhibit No. 3.1(b) to the Current Report of IDEX on Form 8-K dated March 24, 2005, Commission File No. 1-10235) | ||
3 | .2 | Amended and Restated By-Laws of IDEX Corporation (incorporated by reference to Exhibit No. 3.2 to Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on July 17, 1989) | ||
3 | .2(a) | Amended and Restated Article III, Section 13 of the Amended and Restated By-Laws of IDEX Corporation (incorporated by reference to Exhibit No. 3.2(a) to Post-Effective Amendment No. 3 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on February 12, 1990) | ||
4 | .1 | Restated Certificate of Incorporation and By-Laws of IDEX Corporation (filed as Exhibits No. 3.1 through 3.2(a)) | ||
4 | .2 | Specimen Certificate of Common Stock of IDEX Corporation (incorporated by reference to Exhibit No. 4.3 to the Registration Statement on Form S-2 of IDEX, et al., Registration No. 33-42208, as filed on September 16, 1991) | ||
4 | .3 | Credit Agreement, dated as of December 21, 2006, among IDEX Corporation, Bank of America N.A. as Agent and Issuing Bank, and the other financial institutions party hereto (incorporated by reference to Exhibit No. 10.1 to the Current Report of IDEX on Form 8-K dated December 22, 2006, Commission File No. 1-10235) | ||
4 | .3(a) | Amendment No. 2 to Credit Agreement, dated as of September 29, 2008, among IDEX Corporation, Bank of America N.A. as Agent and Issuing Bank, and the other financial institutions party hereto (incorporated by reference to Exhibit No. 4.3(a) to the Quarterly Report of IDEX on Form 10-Q for the quarter ended September 30, 2008, Commission File No. 1-10235) | ||
4 | .4 | Term Loan Agreement, dated April 18, 2008, among IDEX Corporation, Bank of America N.A. as Agent, and the other financial institutions party hereto (incorporated by reference to Exhibit No. 10.1 to the Current Report of IDEX on Form 8-K dated April 18, 2008, Commission File No. 1-10235) | ||
4 | .5 | Master Note Purchase agreement, dated as of June 9, 2010, between IDEX Corporation, J.P. Morgan Securities, Inc. and Wells Fargo Securities as agents, relating to the 2.58% of Senior Notes of IDEX due June 9, 2015 (incorporated by reference to Exhibit No. 4.1 to the Current Report of IDEX on Form 8-K dated June 14, 2010, Commission File No. 1-10235) | ||
*31 | .1 | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) | ||
*31 | .2 | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) | ||
*32 | .1 | Certification pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code | ||
*32 | .2 | Certification pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code |
* | Filed herewith |
29